Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
- FDA Approves New HIV Treatment for Patients With Limited Treatment Options
[On July 2, 2020], the U.S. Food and Drug Administration...
- FDA Approves New HIV Treatment for Patients With Limited Treatment Options
18 Νοε 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills. Charities have welcomed the approval of the...
27 Ιαν 2021 · CABENUVA, a 2-drug co-packaged product of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside...
3 Ιαν 2023 · This statement from the International Antiviral Society–USA updates recommendations for the use of antiretroviral drugs to treat adults with established HIV infection and to prevent HIV infection among persons at risk.
In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly ...
14 Ιουλ 2020 · [On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.
23 Δεκ 2021 · The Food and Drug Administration has approved the first injectable medication for HIV prevention. Health advocates say it could be a game changer in protecting people against AIDS
